Press release
Releases New Report on the CEA Antibodies Market
The elevated levels of carcinoembryonic antigens results in different types of cancers and other conditions such as cholecystitis, lung infection, heavy smoking, inflammatory bowel diseases, peptic and ulcer. High level of carcinoembryonic antigens is also found in the patients who are not diagnosed with cancer. This increases the risk of developing cancer in such patients. Hematoma (blood accumulating under the skin), infection, dizziness and excessive bleeding are some of the risks associated with abnormal levels of CEA.
Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4682
The abnormal levels of CEA in the body can be detected by using arcitumomab, a monoclonal antibody. This is commonly utilized in identification of glycoprotein expression in tissue samples. CEA antibody acts against the CEA, and help treat patients with presence of CEA protein. Hence, this antibody in utilized extensively to treat the patients suffering from CEA associated cancers.
Several drugs (CEA antibody) are currently available in the market that are utilized to treat CEA cancer. Pan CEA and clone II-7 are some of the examples of CEA antibody drugs. Discovery of specific antigens and biomarkers propels the growth of carcinoembryonic antigen antibody market. Similarly, continuous technological advancements in the drugs will also augment the growth of carcinoembryonic antigen antibody market. Likewise, rise in geriatric population also supports the growth of carcinoembryonic antigen antibody market.
This is due to the fact that this class of population is at higher risk for developing CEA associated cancers. The World Health of Organization has estimated that by 2050, around 2 billion people belong to this population. However, lack of awareness and availability of novel technological solutions might pose a challenge to the growth of CEA antibody market.
In 2012, North America accounted for the largest share of the global carcinoembryonic antigen antibody market. This is due to the presence of large number of companies engaged in developing and manufacturing carcinoembryonic antigen antibodies. Also, increasing R&D expenditure by various players in the region will augment the growth of carcinoembryonic antigen antibody market.
Likewise, increasing government initiatives regarding the development of carcinoembryonic antigen antibody will further accentuate the growth of carcinoembryonic antigen antibody market. Europe accounted for the second largest share by revenue in 2012 of global carcinoembryonic antigen antibody market. This large market revenue is attributed to the presence of large geriatric population coupled with increasing healthcare expenditure in the region.
Asia-Pacific along with Rest of the World (RoW) contributed smallest share in the global carcinoembryonic antigen antibody market in 2012. Lack of awareness coupled with presence of few pharmaceutical companies that are engaged in developing and manufacturing carcinoembryonic antigen antibodies restrict the growth of carcinoembryonic antigen antibody market in these two regions of the globe.
Pre-Book Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=4682<ype=S
Some of the major players operating in the carcinoembryonic antigen antibody market include Abbott Laboratories, Siemens Healthcare, bioMerieux, Danaher Corporation (Beckman Coulter), Myriad Genetics, Epigenomics, Qiagen N.V., and Life Technologies Corporation among other significant players.
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Releases New Report on the CEA Antibodies Market here
News-ID: 883479 • Views: …
More Releases from Transparency Market Research
Global SiC Ceramics Market Poised for Robust Growth, Projected to Reach USD 3.1 …
The global silicon carbide (SiC) ceramics market continues to demonstrate strong growth potential, underpinned by accelerating demand from advanced industrial and electronic applications. Valued at US$ 1.8 Billion in 2024, the market is projected to reach US$ 3.1 Billion by 2035, expanding at a compound annual growth rate (CAGR) of 5.2% during the forecast period from 2025 to 2035. This steady expansion reflects the increasing importance of SiC ceramics as…
Furfuryl Alcohol Market to Reach USD 1.34 Billion by 2035, Supported by Rising D …
The global Furfuryl Alcohol Market was valued at US$ 624.3 million in 2024 and is projected to reach US$ 1,341.2 million by 2035, expanding at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2035.
This growth is primarily driven by the rising demand for bio-based and sustainable chemicals, along with the steady expansion of the foundry and metal casting industry, particularly across emerging economies in Asia Pacific.
Gain a…
Air-Entraining Agents Market Outlook 2035: Forecast to Reach US$ 2.48 Billion by …
The global Air-Entraining Agents (AEAs) Market was valued at US$ 1.70 billion in 2024 and is projected to reach US$ 2.48 billion by 2035, expanding at a compound annual growth rate (CAGR) of 3.5% from 2025 to 2035. This steady growth trajectory reflects the essential role AEAs play in modern concrete formulations, particularly in infrastructure projects that demand long-term durability, freeze-thaw resistance, and improved workability.
Despite being a mature segment within…
A2P SMS Market Outlook 2035: Expanding from US$ 71.2 Bn in 2024 to US$ 117.0 Bn …
The global Application-to-Person (A2P) SMS market is entering a phase of steady and resilient expansion, driven by the growing need for secure, reliable, and real-time communication between enterprises and consumers. Valued at US$ 71.2 Bn in 2024, the market is projected to reach US$ 117.0 Bn by 2035, expanding at a CAGR of 4.2% from 2025 to 2035. Despite the rise of internet-based messaging platforms, A2P SMS continues to maintain…
More Releases for CEA
CEA ELISA Kits Market Outlook and Future Projections for 2030
The cea elisa kits market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the…
Carcinoembryonic Antigen (CEA) Market Size, Share | Industry Report 2026
The global Carcinoembryonic Antigen (CEA) Market was valued at $5.3 Billion in 2018 and is forecast to grow at a modest 6.1 % CAGR between 2018 and 2026, culminating in 2026 global sales of $ 9.2 Billion.
Carcinoembryonic AntigenTest is a blood test which identifies the diagnose and manage certain cancer disease like rectum and large intestine. Basically, it is used to check how well treatment is working in certain…
Carcinoembryonic Antigen (CEA) Market Investment Research Report 2017 – 2027
Carcinoembryonic antigen (CEA) is normally found in embryonic entodermal epithelium. Carcinoembryonic antigen is a group of glycoprotein present in the body fluids of the fetus and embryo and in the gastrointestinal tract. Carcinoembryonic antigen is also present in the mucosal cells of the colorectum, gastrointestinal cells, and small amounts are present in the blood. Carcinoembryonic antigen is produced by the gastrointestinal tissues during the development of fetal. CEA is not…
Carcinoembryonic Antigen (CEA) Market foreseen to grow exponentially over 2027
Carcinoembryonic antigen (CEA) is normally found in embryonic entodermal epithelium. Carcinoembryonic antigen is a group of glycoprotein present in the body fluids of the fetus and embryo and in the gastrointestinal tract. Carcinoembryonic antigen is also present in the mucosal cells of the colorectum, gastrointestinal cells, and small amounts are present in the blood. Carcinoembryonic antigen is produced by the gastrointestinal tissues during the development of fetal. CEA is not…
Carcinoembryonic Antigen (CEA) Market to hit $2.7bn by 2023
Carcinoembryonic Antigen (CEA) Market size is driven by increasing incidence rate for cancer disease especially colorectal cancer is one of the important factor contributing to the growth. Global Carcinoembryonic Antigen Market is set to register profitable growth in the near future and surpass USD 2.8 billion by 2023.
This growth is attributed to factors including consistent technology advancements, development of novel biomarkers and growing prevalence of cancer. Global Market Insights,…
CEA Antibodies Market Outlook And Research Survey To 2023
CEA stands for carcinoembryonic antigen, is a protein that is usually produced in developing fetus and disappears or is absent in adults. Production of abnormal amount of CEA protein may lead to cancer. CEA test is performed to measure the level of proteins and check for the recurrence of colon and other cancers in patients already diagnosed with cancer. The normal accepted range of this protein that is non-cancerous in…
